These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32059634)

  • 1. Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation.
    Zern EK; Cheng S; Wolfson AM; Hamilton MA; Zile MR; Solomon SD; Kittleson MM
    Circ Heart Fail; 2020 Feb; 13(2):e006696. PubMed ID: 32059634
    [No Abstract]   [Full Text] [Related]  

  • 2. Sacubitril-Valsartan for the Treatment of Heart Failure: Time for a Paragon?
    Del Buono MG; Bonaventura A; Vecchié A; Wohlford GF; Dixon DL; Van Tassel BW; Abbate A
    J Cardiovasc Pharmacol; 2020 Feb; 75(2):105-107. PubMed ID: 31815825
    [No Abstract]   [Full Text] [Related]  

  • 3. PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction.
    Docherty KF; McMurray JJV
    Cardiovasc Res; 2019 Nov; 115(13):e136-e139. PubMed ID: 31497841
    [No Abstract]   [Full Text] [Related]  

  • 4. In-Hospital Initiation of Sacubitril/Valsartan: A New PARADIGM for Acute Decompensated Heart Failure?
    Bonaventura A; Wohlford GF; Vecchié A; Van Tassel BW; Abbate A
    J Cardiovasc Pharmacol; 2019 Jul; 74(1):1-3. PubMed ID: 31274835
    [No Abstract]   [Full Text] [Related]  

  • 5. Is the glass half full or half empty after PARAGON-HF?
    Cohen-Solal A; Logeart D
    Cardiovasc Res; 2020 Jan; 116(1):e5-e7. PubMed ID: 31850504
    [No Abstract]   [Full Text] [Related]  

  • 6. Sacubitril/valsartan (Entresto) for heart failure.
    Med Lett Drugs Ther; 2015 Aug; 57(1474):107-9. PubMed ID: 26218791
    [No Abstract]   [Full Text] [Related]  

  • 7. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
    Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin Receptor-Neprilysin Inhibition.
    Havakuk O; Elkayam U
    J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):356-364. PubMed ID: 28587583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan.
    Januzzi JL; Camacho A; Piña IL; Rocha R; Williamson KM; Maisel AS; Felker GM; Prescott MF; Butler J; Solomon SD;
    Circ Heart Fail; 2020 Jun; 13(6):e006946. PubMed ID: 32482089
    [No Abstract]   [Full Text] [Related]  

  • 10. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
    Kang DH; Park SJ; Shin SH; Hong GR; Lee S; Kim MS; Yun SC; Song JM; Park SW; Kim JJ
    Circulation; 2019 Mar; 139(11):1354-1365. PubMed ID: 30586756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacubitril/valsartan improves medium-term reverse left ventricular remodeling: why wait?
    Santangelo G; Bursi F; Toriello F; Valli F; Tombolini E; Torta D; Bosotti L; Massironi L; Carugo S
    J Cardiovasc Med (Hagerstown); 2019 Oct; 20(10):727-729. PubMed ID: 31169634
    [No Abstract]   [Full Text] [Related]  

  • 12. Confirmatory Trials for Drugs Approved on a Single Trial.
    Haslam A; Prasad V
    Circ Cardiovasc Qual Outcomes; 2019 Jun; 12(6):e005494. PubMed ID: 31137954
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from ramipril to sacubitril/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction.
    Okutucu S; Sabanoglu C; Yetis Sayin B; Aksoy H; Bursa N; Oto A
    Acta Cardiol; 2020 Feb; 75(1):20-25. PubMed ID: 30513267
    [No Abstract]   [Full Text] [Related]  

  • 15. In heart failure with reduced ejection fraction patients' left ventricular global longitudinal strain is enhanced after 1-year therapy with sacubitril/valsartan compared with conventional therapy with angiotensin-converting enzyme-inhibitors or AT1 blockers: results from a retrospective cohort study.
    De Vecchis R; Paccone A; Di Maio M
    J Cardiovasc Med (Hagerstown); 2019 Dec; 20(12):857-858. PubMed ID: 31460889
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of sacubutril/valsartan on nutritional status in heart failure with reduced ejection fraction.
    Dereli S; Bayramoğlu A; Kaya A
    J Cardiovasc Med (Hagerstown); 2020 Jan; 21(1):13-20. PubMed ID: 31714330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
    Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
    Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).
    Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
    Circulation; 2016 Jun; 133(23):2254-62. PubMed ID: 27143684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan.
    Sokos GG; Raina A
    Vasc Health Risk Manag; 2020; 16():41-51. PubMed ID: 32021227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016.
    Chen X; Schaufelberger M; Fu M
    J Cardiovasc Med (Hagerstown); 2020 Jan; 21(1):6-12. PubMed ID: 31789711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.